This register continues to churn just as it was below 3c.
The DSA agreement should bear fruits imminently. A few contracts and endorsements from a few institutions before the EOY should light up the stock as they set up offices in Europe.
FDA approval is the wildcard, ePat have submitted and since this is a Class 1 device approval could come well before Q2 next year.
